Mizuho analyst Salim Syed raised the firm’s price target on Gilead Sciences to $101 from $88 and keeps a Buy rating on the shares. In a post-Q4 model update, the analyst increased the firm’s peak sales estimates for Gilead’s HIV business to $20B from $19B.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on GILD: